comprehensive -WSS

comprehensive

author：entertainment 2025-09-03 03:24:19 - browse：35321

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Do masks work? RCTs can't tell us

explore

WSS

UnitedHealth’s board chair also owns a personal investment firm

FDA warns J&J's Abiomed: We will regulate your software

The strategy behind pharma's lawsuits over drug pricing reform

STAT's guide to the next generation of CAR

Weight bias in eating disorder treatment complicated by new weight loss drugs

Lawmakers consider Medicare pay reforms for doctors

entertainment

comprehensive

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

Death of patient in Alzheimer’s trial raises question of possible risks

Dobbs anniversary: the lost opportunity of abortion as health care

Colonoscopy at 40? Study finds a possible benefit

United colonoscopy coverage change 'may cost lives,' doctors say

New guidelines on severe brain injury complicate already difficult decisions

United colonoscopy coverage change 'may cost lives,' doctors say

Do masks work? RCTs can't tell us

Peter Hotez and the public health issue of online harassment

Will Ozempic

hotspot

WATCH: Why do fingernails fall off when they're damaged?

In areas with more Black doctors, Black people live longer

Death of patient in Alzheimer’s trial raises question of possible risks

CEOs share strategies for surviving biotech slump

Paxlovid study fails to answer questions over benefit for broader groups

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

hotspot

focus

explore

hotspot